Anti-CD7 CAR-T Cells RD13-02 clinical trials
Its developmentBy Nanjing Bioheng Biotech, step by step1 company-led study, furthest early phase 1: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-CD7 CAR-T Cells RD13-02 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CD7 CAR-T Cells RD13-02 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2023 (5)
| Year | Studies |
|---|---|
| 2023 | 5 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 7
Nanjing Bioheng Biotech Co., Ltd. (1) · MEI HENG (1) · Henan Cancer Hospital (1) · He Huang (1) · Kai Lin Xu,MD (1) · Xiaoyu Zhu (1) · Wuhan Union Hospital, China (1) · Institute of Hematology & Blood Diseases Hospital, China (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-CD7 CAR-T Cells RD13-02.
- Dec 2026RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell MalignanciesPhase 1 · Wuhan Union Hospital, China
Studies
Open first, then newest update. How each study uses Anti-CD7 CAR-T Cells RD13-02 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell MalignanciesRecruitingPhase 1Wuhan Union Hospital, ChinaNCT06732492Written as RD13-02 cell infusion
- CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic AnemiaSuspendedPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT06622694Written as RD13-02
- Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological MalignanciesCompletedEarly Phase 1MEI HENGNCT05895994Written as RD13-02 cell infusion
- A Study on the Safety, Preliminary Efficacy, and Cellular Kinetics of Allo-CD7 CAR-T Cells in T1DMActive, not recruitingEarly Phase 1Nanjing Bioheng Biotech Co., Ltd.NCT07142161Written as RD13-02 cell infusion
- RD13-02 for Patients With r/r CD7+ T Cell Hematologic MalignanciesCompletedEarly Phase 1Henan Cancer HospitalNCT05923541Written as RD13-02 cell infusion
- CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBLCompletedEarly Phase 1He HuangNCT05716113Written as RD13-02 cell infusion
- Research Development(RD)13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7(CD7)+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)CompletedEarly Phase 1Kai Lin Xu,MDNCT05907603Written as RD13-02 cell infusion
- RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBLCompletedEarly Phase 1Xiaoyu ZhuNCT05902845Written as RD13-02 cell infusion
What changed recently
From the registry's own updates since Oct 19, 2026.
Stopped1
- CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic AnemiaSuspendedNov 4, 2026NCT06622694